BioXcel Therapeutics (BTAI) executive Yocca acquired 68 shares
Insider transactions reported
Frank Yocca (Chief Scientific Officer at BioXcel Therapeutics Inc., BTAI) reported that they acquired 68 shares between Mar 14, 2026 and Mar 15, 2026. After these transactions the filing shows 6,520 shares held directly.
- Reporting person
- Yocca Frank
- Role
- Chief Scientific Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 14, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +33 | - | - | 6,485 direct |
| Mar 15, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +35 | - | - | 6,520 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Mar 14, 2026 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 33 Common Stock1, 2 | -33 | - | - | 97 direct |
| Mar 15, 2026 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 35 Common Stock1, 3 | -35 | - | - | 247 direct |
Holdings before and after
- Common Stock: 6,452 to 6,520 direct
- Restricted Stock Units: 130 to 247 direct
Footnotes from the filing
- 1. Each Restricted Stock Unit ( RSU ) represents a contingent right to receive one share of the Issuer's Common Stock.
- 2. On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Yocca report in this BTAI Form 4?
Frank Yocca (Chief Scientific Officer at BioXcel Therapeutics Inc., BTAI) reported that they acquired 68 shares between Mar 14, 2026 and Mar 15, 2026. After these transactions the filing shows 6,520 shares held directly.
How many BTAI shares does Yocca hold after this filing?
The filing shows 6,520 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for BTAI
Across the 10 sessions after earlier BTAI headlines, the stock closed higher 5 times and lower 5 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BTAI | SPY |
|---|---|---|---|
| Mar 12, 2026 | BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering | -1.3% | -1.5% |
| Mar 10, 2026 | BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering | -10.4% | -0.2% |
| Mar 5, 2026 | BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal | -2.4% | -0.6% |
| Feb 19, 2026 | BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia | +2.5% | -0.3% |
| Feb 12, 2026 | BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting | -4.9% | -1.5% |
| Jan 20, 2026 | BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting | +2.7% | -2.0% |
Earlier insider filings at BTAI
- Jan 13, 2026SEC Form 4 filed by Director Laumas Sandeep
- Jan 13, 2026SEC Form 4 filed by Director Patni Rajiv
- Jan 13, 2026SEC Form 4 filed by Director Mueller Peter
- Jan 13, 2026SEC Form 4 filed by Director Votruba Michal
- Jan 13, 2026SEC Form 4 filed by Director Miller Michael Patrick
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Follow BTAI and get a push notification the moment its next story breaks.